SCHEMBL1960448

SCHEMBL1960448

CSc1ccc(C(O)c2cc3cc(F)cnc3n2S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.41
MAPT P10636 4/20 0.38
TP53 P04637 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 3/20 0.33
PTGS2 P35354 1/20 0.33
ALDH1A1 P00352 6/20 0.33
TSHR P16473 4/20 0.33
HSD17B10 Q99714 3/20 0.33
KMT2A Q03164 1/20 0.33
HTR6 P50406 1/20 0.32
USP9X Q93008 1/20 0.32
PTGDR Q13258 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
ALDH3A1 P30838 1/20 0.31
ESR1 P03372 1/20 0.31
LMNA P02545 2/20 0.31
HTT P42858 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1962099 0.85 RECQL (0.50) RECQLMAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL1960830 0.80 HDAC3 (0.41) MAPTTP53SMN1; SMN2HPGDPTGS2
SCHEMBL1963085 0.77 RECQL (0.39) RECQLMAPTALDH1A1KMT2AHTR6
SCHEMBL1963034 0.73 RECQL (0.35) RECQLMAPTTP53HPGDALDH1A1
SCHEMBL1963563 0.72 RECQL (0.36) RECQLALDH1A1HTR6
SCHEMBL1959161 0.72 GCK (0.33) MAPTTP53SMN1; SMN2ALDH1A1KMT2A
SCHEMBL1961245 0.72 CHRM3 (0.33) MAPTTP53SMN1; SMN2KMT2AHTR6
SCHEMBL2924156 0.71 RECQL (0.48) RECQLMAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL1962390 0.71 RECQL (0.44) RECQLMAPTTP53ALDH1A1HTR6
SCHEMBL1959066 0.70 ALDH1A1 (0.39) RECQLMAPTSMN1; SMN2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 RECQL 3296/4885MAPT 4347/4885TP53 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.